Cardiol Therapeutics (CRDL) is the lead sponsor of 1 active clinical trials listed on ClinicalTrials.gov[2], including 1 Phase 3[1].
Trial NCT06708299[3] evaluates CardiolRx in Recurrent Pericarditis with a target enrollment of 110 participants.
No Form 4 insider filings for CRDL were recorded at the SEC in the past 30 days[4].